

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>Jackson Denise L</u> (Last) (First) (Middle) 12400 HIGH BLUFF DRIVE (Street) SAN DIEGO CA 92130 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>AMN HEALTHCARE SERVICES INC [AMN]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) Chief Legal Officer
	3. Date of Earliest Transaction (Month/Day/Year) 01/03/2021	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	01/03/2021		M ⁽¹⁾		1,339	A	\$0.00	21,491	D	
Common Stock	01/03/2021		F ⁽²⁾		551	D	\$68.25	20,940	D	
Common Stock	01/05/2021		M ⁽¹⁾		1,009	A	\$0.00	21,949	D	
Common Stock	01/05/2021		F ⁽²⁾		393	D	\$68.92	21,556	D	
Common Stock	01/05/2021		A ⁽³⁾		3,442	A	\$0.00	24,998	D	
Common Stock	01/05/2021		F ⁽²⁾		1,186	D	\$68.92	23,812	D	
Common Stock	01/05/2021		S ⁽⁴⁾		788	D	\$69.8515 ⁽⁵⁾	23,024	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Restricted Stock Units	(6)	01/03/2021		M			1,339	(7)	(8)	Common Stock	1,339	\$0.00	1,379	D	
Restricted Stock Units	(6)	01/04/2021		A		4,642		(9)	(8)	Common Stock	4,642	\$0.00	4,642	D	
Restricted Stock Units	(6)	01/05/2021		M		1,009		(10)	(8)	Common Stock	1,009	\$0.00	0	D	

Explanation of Responses:

- Common Stock acquired on the vesting of Restricted Stock Units (RSUs).
- Number of shares withheld for tax purposes.
- The acquisition of Common Stock set forth in this row resulted from the vesting of a Performance Restricted Stock Unit ("PRSU") award granted by the Company on January 5, 2018. The ultimate number of PRSUs that could have been earned and vested under this award depended on (1) the total shareholder return for the Company relative to the companies in the Russell 2000 Index as of December 31, 2017 for the 3-year period beginning on January 1, 2018 and ended December 31, 2020 ("Relative TSR") and (2) whether the Company's absolute total shareholder return for the same period was positive or negative (collectively, the "TSR Measurement"). The Compensation Committee performed the TSR Measurement for this award on January 4, 2021. The Company's Relative TSR measured in the 78th percentile and its absolute total shareholder return for the period was positive. Based on these results, the maximum amount of PRSUs for this award were deemed earned and vested.
- The sale of 788 shares of AMN Common Stock was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- The price reported in this row represents a weighted average price of \$69.8515 per share. These shares were sold in multiple transactions at prices ranging from \$69.83 to \$69.875, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- The RSUs identified in this row were granted pursuant to the AMN Healthcare 2017 Equity Plan. Each RSU represents a contingent right to receive one share of AMN Common Stock.
- The RSUs identified in this row were granted on January 3, 2019 and vest in three tranches on each of the first, second and third anniversaries of the grant date.
- RSUs do not have an expiration date.
- The RSUs identified in this row were granted on January 4, 2021 and vest in three tranches on each of the first, second and third anniversaries of the grant date.
- The RSUs identified in this row were granted on January 5, 2018 and vest in three tranches on each of the first, second and third anniversaries of the grant date.

Remarks:

/s/ Denise L. Jackson 01/05/2021
 ** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
 ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
 Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

